Rhumbline Advisers Voyager Therapeutics, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 69,143 shares of VYGR stock, worth $399,646. This represents 0.0% of its overall portfolio holdings.

Number of Shares
69,143
Previous 72,461 4.58%
Holding current value
$399,646
Previous $573,000 29.49%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$5.77 - $9.27 $19,144 - $30,757
-3,318 Reduced 4.58%
69,143 $404,000
Q2 2024

Aug 01, 2024
BUY
$7.42 - $10.54 $193,023 - $274,187
26,014 Added 56.01%
72,461 $573,000
Q1 2024

May 09, 2024
BUY
$7.15 - $10.84 $26,533 - $40,227
3,711 Added 8.68%
46,447 $432,000
Q4 2023

Feb 08, 2024
SELL
$6.28 - $8.81 $1,909 - $2,678
-304 Reduced 0.71%
42,736 $360,000
Q3 2023

Nov 09, 2023
BUY
$7.55 - $11.25 $12,298 - $18,326
1,629 Added 3.93%
43,040 $333,000
Q2 2023

Aug 08, 2023
BUY
$6.94 - $13.99 $287,392 - $579,339
41,411 New
41,411 $474,000
Q2 2021

Aug 05, 2021
SELL
$3.94 - $5.44 $133,439 - $184,241
-33,868 Closed
0 $0
Q1 2021

May 06, 2021
SELL
$4.61 - $9.04 $5,993 - $11,751
-1,300 Reduced 3.7%
33,868 $160,000
Q4 2020

Feb 10, 2021
BUY
$7.15 - $12.28 $22,165 - $38,068
3,100 Added 9.67%
35,168 $251,000
Q3 2020

Nov 12, 2020
SELL
$10.01 - $13.75 $49,499 - $67,993
-4,945 Reduced 13.36%
32,068 $342,000
Q2 2020

Aug 13, 2020
BUY
$8.05 - $14.21 $27,820 - $49,109
3,456 Added 10.3%
37,013 $467,000
Q1 2020

May 06, 2020
SELL
$6.8 - $14.66 $6,963 - $15,011
-1,024 Reduced 2.96%
33,557 $307,000
Q4 2019

Feb 05, 2020
BUY
$12.82 - $16.85 $27,575 - $36,244
2,151 Added 6.63%
34,581 $482,000
Q3 2019

Oct 23, 2019
BUY
$16.31 - $28.29 $1,141 - $1,980
70 Added 0.22%
32,430 $558,000
Q2 2019

Aug 14, 2019
BUY
$19.18 - $27.88 $91,411 - $132,876
4,766 Added 17.27%
32,360 $881,000
Q1 2019

May 01, 2019
SELL
$8.0 - $19.66 $3,160 - $7,765
-395 Reduced 1.41%
27,594 $528,000
Q4 2018

Jan 31, 2019
BUY
$8.59 - $18.05 $78,048 - $164,002
9,086 Added 48.07%
27,989 $263,000
Q3 2018

Nov 07, 2018
SELL
$17.11 - $21.74 $23,184 - $29,457
-1,355 Reduced 6.69%
18,903 $358,000
Q2 2018

Aug 06, 2018
BUY
$16.76 - $23.92 $52,492 - $74,917
3,132 Added 18.29%
20,258 $396,000
Q1 2018

May 02, 2018
BUY
$16.16 - $31.31 $40,286 - $78,055
2,493 Added 17.04%
17,126 $322,000
Q4 2017

Feb 09, 2018
SELL
$12.26 - $25.88 $19,591 - $41,356
-1,598 Reduced 9.85%
14,633 $243,000
Q3 2017

Nov 06, 2017
BUY
$8.37 - $20.59 $135,853 - $334,196
16,231
16,231 $334,000

Others Institutions Holding VYGR

# of Institutions
130
Shares Held
34.7M
Call Options Held
39.7K
Put Options Held
34.6K
View Full List

About Voyager Therapeutics, Inc.

VYGR Quotes by TradingView
  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $223M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email